Last mentioned: Mar 24, 2026
Final Departure
Official announcement of Marks leaving the agency for the second time.
Initial Friction
Reports surface of Marks considering resignation amid administrative policy shifts.
SCOTUS Ruling
Supreme Court dismisses challenge to mifepristone access on standing grounds, preserving status quo.
Retail Pharmacy Entry
Major chains CVS and Walgreens receive certification to dispense abortion pills.
Dobbs Decision
Supreme Court overturns Roe v. Wade, leading to state-level bans.
Telehealth Expansion
FDA permanently removes in-person dispensing requirements, allowing mail-order access.
Operation Warp Speed
Plays a central role in the emergency use authorizations for COVID-19 vaccines.
Appointed Director
Promoted to Director of CBER, overseeing the 'Gold Standard' of vaccine review.
Joins FDA
Dr. Peter Marks joins the FDA as Deputy Director of CBER.
Initial FDA Approval
FDA approves Mifepristone for medical termination of early pregnancy.
Medication abortion now accounts for the majority of pregnancy terminations in the U.S., driven by telehealth expansion and state shield laws. This shift has triggered a wave of regulatory counter-measures from opponents, focusing on the Comstock Act and FDA approval processes.
Dr. Peter Marks, the long-serving head of the FDA’s vaccine division, is stepping down for the second time as the Trump administration intensifies its 'Make America Healthy Again' initiatives. His exit marks a critical turning point for the Center for Biologics Evaluation and Research and signals a potential shift in the agency's rigorous approval standards.
FDA Commissioner Marty Makary is reportedly attempting to hire Dr. Tracy Beth Hoeg to lead a new initiative focused on antidepressant safety. The move is tied to a proposed 'bold new warning' for SSRIs and SNRIs, potentially addressing persistent side effects that have long been a point of contention between regulators and the pharmaceutical industry.
The U.S. Food and Drug Administration is introducing a performance-based bonus system to reward staffers who complete drug reviews ahead of schedule. This regulatory shift aims to clear backlogs and could significantly shorten the path to market for biotech startups and their venture backers.